Y-mAbs’ I-Omburtamab Offers Another Example Of The Limits To US FDA’s Regulatory Flexibility

 
• By Derrick Gingery
flexibility
FDA flexibility may not be extensive enough to approve I-omburtamab. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers